Prediction of differentiation levels in lung adenocarcinoma using peripheral blood inflammatory cytokines and tumor markers
PLOS One · 2026
DOI: 10.1371/journal.pone.0339414 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Yang Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, The Second affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Lung Neoplasms, Adenocarcinoma of Lung, Cytokines. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Lung Adenocarcinoma (LUAD) has highly aggressive and lethal, and its degree of differentiation significantly influences prognosis and treatment strategies, yet accurate prediction remains challenging. To assess the predictive value of combining peripheral blood inflammatory markers, such as the aggregate index of systemic inflammation (AISI), with tumor markers, including Carcinoembryonic Antigen (CEA) and Cytokeratin 19 fragment antigen 21−1(CYFRA21−1), etc, for determining LUAD differentiation levels.
Methods
This retrospective study included 203 LUAD patients treated at Chongqing Medical University’s Second Affiliated Hospital, categorized by low and high differentiation. Demographic, clinical, and laboratory data including peripheral blood inflammatory and tumor markers were analyzed. A multivariate logistic regression model evaluated these markers’ predictive accuracy.
Results
AISI (OR = 1.64, 95% CI = 1.08–2.58, p = 0.024), CEA (OR = 1.02, 95% CI = 1.00–1.04, p = 0.0497), ferritin (OR = 1.01, 95% CI = 1.00–1.01, p = 0.010), and Progastrin Releasing Peptide (ProGRP) (OR = 1.03, 95% CI = 1.00–1.07, p = 0.047) were risk factors of low differentiation LUAD. The model achieved an Area Under Curve(AUC) of 0.795 (95%CI: 0.726–0.864) for distinguishing low from high differentiation, with decision curve analysis confirming clinical utility.
Conclusion
This model, combining inflammatory and tumor markers, effectively predicts LUAD differentiation, aiding personalized treatment planning, enhancing therapeutic outcomes, and supporting early LUAD detection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, The Second affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Endocrinology, The Second affiliated Hospital of Chongqing Medical University, Chongqing, China.
ORCID-Profile: Depeng Jiang
Zitieren
APA
Li, Y., Wu, J., Long, M., Zeng, T., & Jiang, D. (2026). Prediction of differentiation levels in lung adenocarcinoma using peripheral blood inflammatory cytokines and tumor markers. PLOS One. https://doi.org/10.1371/journal.pone.0339414
Vancouver
Li Y, Wu J, Long M, Zeng T, Jiang D. Prediction of differentiation levels in lung adenocarcinoma using peripheral blood inflammatory cytokines and tumor markers. PLOS One. 2026. doi:10.1371/journal.pone.0339414
BibTeX
@article{Li2026,
author = {Li, Yang and Wu, Jiahuan and Long, Meiling and Zeng, Tingting and Jiang, Depeng},
title = {Prediction of differentiation levels in lung adenocarcinoma using peripheral blood inflammatory cytokines and tumor markers},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0339414}
}
EUVIMED